Salarius fixes pro forma math in merger filing

Accepted by SEC EDGAR 08/26/2025 - 04:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. filed an amended current report to correct an immaterial mathematical error in its unaudited pro forma consolidated combined financial information related to its potential merger partner, Decoy Therapeutics Inc.

The correction applies to the pro forma balance sheet and statement of operations as of June 30, 2025 and December 31, 2024. The company states that no other parts of the original report are being changed and that the amendment does not provide any update on developments at Salarius or its subsidiaries since the original filing.

8-K Event Classification

Item 9.01 — Financial Statements and Exhibits

1 item

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Salarius Pharmaceuticals (SLRX) change in this 8-K/A amendment?

The amendment corrects an immaterial mathematical error in Salarius Pharmaceuticals' unaudited pro forma consolidated combined financial information related to its potential merger with Decoy Therapeutics Inc., covering data as of June 30, 2025 and December 31, 2024.

Does this Salarius (SLRX) amendment affect the proposed merger with Decoy Therapeutics?

The amendment states that it only corrects an immaterial mathematical error in unaudited pro forma financial information about Salarius and Decoy Therapeutics and does not amend any other item or provide further updates on the merger or the companies' businesses.

Which financial statements are included in the updated exhibit for Salarius (SLRX)?

The updated exhibit includes an unaudited pro forma balance sheet as of June 30, 2025 and statements of operations for Salarius Pharmaceuticals, Inc. and Decoy Therapeutics Inc. as of June 30, 2025 and December 31, 2024.

How does Salarius (SLRX) describe the significance of the error being corrected?

Salarius describes the issue as an immaterial mathematical error in its unaudited pro forma consolidated combined financial information, indicating the correction does not reflect a broader change to its reporting.

Does the Salarius (SLRX) 8-K/A provide new business or operational updates?

No. The amendment states that it does not provide an update or discussion of any developments at Salarius Pharmaceuticals or its subsidiaries after the date of the original report, and only addresses the specified pro forma math correction.

Which exhibit was updated in the Salarius Pharmaceuticals (SLRX) amendment?

Exhibit 99.3 was updated and now contains the corrected unaudited pro forma balance sheet and statements of operations for Salarius Pharmaceuticals, Inc. and Decoy Therapeutics Inc. for the specified dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001615219FALSE2450 Holcombe Blvd.Suite XHoustonTX00016152192025-08-152025-08-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K/A

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2025

SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

001-36812

46-5087339

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

2450 Holcombe Blvd. Suite X Houston, TX

77021

(Address of principal executive offices)

(Zip Code)

(713) 913-5608
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class						Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001						SLRX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

EXPLANATORY NOTE

This Amendment No. 1 on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K of Salarius Pharmaceuticals, Inc., a Delaware corporation (the “Company”), filed on August 22, 2025 (the “Original Report”), in which the Company provided an update regarding its potential merger partner, Decoy Therapeutics Inc. (“Decoy”) and its business.

This Amendment No. 1 is being filed to correct an immaterial mathematical error in the Company’s unaudited pro forma consolidated combined financial information as of June 30, 2025 and December 31, 2024, which was filed with the Original Report. This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company or its subsidiaries, subsequent to the filing date of the Original Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.3

Unaudited Pro Forma Balance Sheet as of June 30, 2025 and Statement of Operations of Salarius Pharmaceuticals, Inc. and Decoy Therapeutics Inc. as of June 30, 2025 and December 31, 2024

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: August 26, 2025

By:

/s/ Mark J. Rosenblum

Mark J. Rosenblum Acting Chief Executive Officer, Executive Vice President & Chief Financial Officer